REFERENCES
1. Jian N, Yu L, Ma L, Zheng B, Huang W. BCG therapy in bladder cancer and its tumor microenvironment interactions. Clin Microbiol Rev. 2025;38:e0021224.
2. Huang X, Wang X, He Z, et al. Mechanisms, clinical trials, and new treatments for BCG-unresponsive in nonmuscle invasive bladder cancer. Cancer Med. 2025;14:e71243.
3. Abou Chakra M, Duquesne I, O’Donnell MA. Decoding immune mechanisms in BCG-unresponsive non-muscle invasive bladder cancer. Front Biosci. 2026;31:47606.
4. Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024;212:3-10.
5. Powles T, Bellmunt J, Comperat E, et al.; ESMO Guidelines Committee. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35:485-90.
6. Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline: 2024 Amendment. J Urol. 2024;211:533-8.
7. Kates M, Matoso A, Choi W, et al. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res. 2020;26:882-91.
8. Pan W, Miao Q, Yin W, et al. The role and clinical applications of exosomes in cancer drug resistance. Cancer Drug Resist. 2024;7:43.
9. Archer M, Lin KM, Kolanukuduru KP, et al. Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response. Am J Clin Exp Urol. 2024;12:331-51.
10. Bhattacharya S, Mohanty A, Achuthan S, et al. Group behavior and emergence of cancer drug resistance. Trends Cancer. 2021;7:323-34.
11. Brena D, Huang MB, Bond V. Extracellular vesicle-mediated transport: reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis. Transl Oncol. 2022;15:101286.
12. Wang J, Zeng H, Zhang H, Han Y. The role of exosomal PD-L1 in tumor immunotherapy. Transl Oncol. 2021;14:101047.
13. Sun DS, Chang HH. Extracellular vesicles: function, resilience, biomarker, bioengineering, and clinical implications. Tzu Chi Med J. 2024;36:251-9.
14. Hu T, Shi R, Gu Y, et al. Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties. Wiley Interdiscip Rev RNA. 2023;15:e1822.
15. Sultana F, Ghosh A. Exosome: the hidden messengers in cancer detection and immunotherapy. Urol Oncol. 2025;43:609-27.
16. Dou X, Feng C, Li J, Jiang E, Shang Z. Extracellular vesicle-mediated crosstalk in tumor microenvironment dominates tumor fate. Trends Cell Biol. 2025;35:230-47.
17. Hu S, Hu Y, Yan W. Extracellular vesicle-mediated interorgan communication in metabolic diseases. Trends Endocrinol Metab. 2023;34:571-82.
18. Huang CS, Yu DS, Jiang SS, Wu YS, Ho JY, Yu CP. Extracellular vesicle-mediated regulation of H3C14 contributes to gemcitabine resistance in bladder cancer. J Extracell Vesicles. 2025;14:e70179.
19. Chung WM, Molony RD, Lee YF. Non-stem bladder cancer cell-derived extracellular vesicles promote cancer stem cell survival in response to chemotherapy. Stem Cell Res Ther. 2021;12:533.
20. Huang CS, Ho JY, Chiang JH, Yu CP, Yu DS. Exosome-derived LINC00960 and LINC02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder cancer cells. Cells. 2020;9:1419.
21. Wu ATH, Srivastava P, Yadav VK, et al. Ovatodiolide, isolated from Anisomeles indica, suppresses bladder carcinogenesis through suppression of mTOR/β-catenin/CDK6 and exosomal miR-21 derived from M2 tumor-associated macrophages. Toxicol Appl Pharmacol. 2020;401:115109.
22. Ortiz-Bonilla CJ, Molony RD, Miyamoto H, Messing E, Lee YF. Bacillus Calmette-Guérin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer. Front Immunol. 2026;17:1707754.
23. Tomiyama E, Fujita K, Hashimoto M, Uemura H, Nonomura N. Urinary markers for bladder cancer diagnosis: a review of current status and future challenges. Int J Urol. 2024;31:208-19.
24. Urabe F, Kimura T, Ito K, et al. Urinary extracellular vesicles: a rising star in bladder cancer management. Transl Androl Urol. 2021;10:1878-89.
25. Droste M, Puhka M, van Royen ME, et al. Roadblocks of urinary EV biomarkers: moving toward the clinic. J Extracell Vesicles. 2025;14:e70120.
26. Sun N, Zhang Z, Yang X, et al. Unveiling urinary extracellular vesicle mRNA signature for early diagnosis and prognosis of bladder cancer. Theranostics. 2025;15:1272-84.
27. Kasiński D, Szeliski K, Drewa T, Pokrywczyńska M. Extracellular vesicles-a new player in the development of urinary bladder cancer. Ther Adv Med Oncol. 2025;17:17588359241297529.
28. Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021;39:41-51.
29. Welsh JA, Goberdhan DCI, O’Driscoll L, et al.; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
30. EV-TRACK Consortium; Van Deun J, Mestdagh P, Agostinis P, et al.. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017;14:228-32.
31. Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of exosome composition. Cell. 2019;177:428-45.e18.
32. de Jong OG, Murphy DE, Mäger I, et al. A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA. Nat Commun. 2020;11:1113.
33. Mateescu B, Kowal EJ, van Balkom BW, et al. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA - an ISEV position paper. J Extracell Vesicles. 2017;6:1286095.
34. Gupta D, Zickler AM, El Andaloussi S. Dosing extracellular vesicles. Adv Drug Deliv Rev. 2021;178:113961.
35. Vago R, Radano G, Zocco D, Zarovni N. Urine stabilization and normalization strategies favor unbiased analysis of urinary EV content. Sci Rep. 2022;12:17663.
36. Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29:653-68.
37. Pan Y, Lu X, Shu G, et al. Extracellular vesicle-mediated transfer of lncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma. Cancer Res. 2023;83:103-16.
38. He J, He J, Min L, et al. Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma. Int J Cancer. 2020;146:1052-63.
39. Del Re M, Conteduca V, Crucitta S, et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. Prostate Cancer Prostatic Dis. 2021;24:524-31.
40. Peak TC, Panigrahi GK, Praharaj PP, et al. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer. Mol Carcinog. 2020;59:62-72.
41. Shan G, Gu J, Zhou D, et al. Cancer-associated fibroblast-secreted exosomal miR-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-β signaling pathway. Exp Mol Med. 2020;52:1809-22.
42. Hirpara J, Thuya WL, Cheow SH, et al. Tumor-derived extracellular vesicles convey solute transporters to induce bioenergetic dependence shift contributing to treatment resistance. Theranostics. 2024;14:6350-69.
43. Han J, Xu K, Xu T, Song Q, Duan T, Yang J. The functional regulation between extracellular vesicles and the DNA damage responses. Mutat Res Rev Mutat Res. 2025;795:108532.
44. Hu X, He C, Zhang L, et al. Mesenchymal stem cell-derived exosomes attenuate DNA damage response induced by cisplatin and bleomycin. Mutat Res Genet Toxicol Environ Mutagen. 2023;889:503651.
45. Sun H, Zhu R, Guo X, et al. Exosome miR-101-3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2. Pathol Res Pract. 2024;256:155271.
46. Tsujino T, Sugito N, Taniguchi K, et al. MicroRNA-143/Musashi-2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer. Cancer Sci. 2019;110:2189-99.
47. Gellings P, Galeas-Pena M, Morici LA. Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy. Clin Exp Med. 2023;23:519-27.
48. Ranti D, Yu H, Salomé B, et al. HLA-E and NKG2A mediate resistance to BCG immunotherapy in non-muscle-invasive bladder cancer. bioRxiv. 2025.
49. Feng R, Li Z, Ge G, Wang C, Jia Y, Ouyang J. Cancer-associated fibroblast-derived extracellular vesicles mediate immune escape of bladder cancer via PD-L1/PD-1 expression. Endocr Metab Immune Disord Drug Targets. 2023;23:1410-20.
50. Gorgulho J, Loosen SH, Masood R, et al. Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy. J Exp Clin Cancer Res. 2024;43:298.
51. Tosev G, Wahafu W, Reimold P, et al. Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. Sci Rep. 2021;11:14244.
52. Liao C, Hu L, Zhang Q. Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma. Nat Rev Urol. 2024;21:662-75.
53. Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125:1185-96.
54. Zhang X, Zhang X, Deng X, et al. Prostate cancer stem cell dynamics in the evolution of drug resistance. Int J Surg. 2025;111:5403-19.
55. Zhou M, Wang L, Yu B, et al. How advanced are extracellular vesicles in renal cell carcinoma? For diagnostic and therapeutic frontiers. Int J Nanomedicine. 2025;20:10963-76.
56. Hatano K, Fujita K. Extracellular vesicles in prostate cancer: a narrative review. Transl Androl Urol. 2021;10:1890-907.
57. Soekmadji C, Riches JD, Russell PJ, et al.; Australian Prostate Cancer Collaboration BioResource. Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Oncotarget. 2017;8:52237-55.
58. Murakami T, Minami K, Harabayashi T, et al. Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients. Sci Rep. 2024;14:6801.
59. Tomiyama E, Fujita K, Matsuzaki K, et al. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer. Br J Cancer. 2022;127:1312-23.
60. Ertl I, Shariat SF, Berger W, Englinger B. Preclinical models for bladder cancer therapy research. Curr Opin Urol. 2024;34:244-50.
